John Gnann to Male
This is a "connection" page, showing publications John Gnann has written about Male.
Connection Strength
0.243
-
Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease. Emerg Infect Dis. 2019 11; 25(11):2064-2073.
Score: 0.037
-
Impact of a rapid multiplex polymerase chain reaction blood culture identification technology on outcomes in patients with vancomycin-resistant Enterococcal bacteremia. Infect Dis (Lond). 2016 Oct; 48(10):732-7.
Score: 0.029
-
Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy. Clin Infect Dis. 2015 Sep 01; 61(5):683-91.
Score: 0.027
-
Mosquito bites and eastern equine encephalitis. QJM. 2014 May; 107(5):397-8.
Score: 0.024
-
Clinical practice. Herpes zoster. N Engl J Med. 2002 Aug 01; 347(5):340-6.
Score: 0.011
-
Risk factors for mortality and progression to severe COVID-19 disease in the Southeast region in the United States: A report from the SEUS Study Group. Infect Control Hosp Epidemiol. 2021 12; 42(12):1464-1472.
Score: 0.010
-
Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000 Apr; 30 Suppl 1:S72-6.
Score: 0.009
-
Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999 Jan; 179(1):9-15.
Score: 0.009
-
Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/AIDS Clinical Trials Group, Herpes Zoster Study Group. Antimicrob Agents Chemother. 1998 May; 42(5):1139-45.
Score: 0.008
-
Histoplasma meets Crohn's disease: a rare case of new-onset ascites. BMJ Case Rep. 2018 Apr 17; 2018.
Score: 0.008
-
West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infect Dis. 2014 May 09; 14:248.
Score: 0.006
-
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 01; 208(9):1386-90.
Score: 0.006
-
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15; 208(4):559-63.
Score: 0.006
-
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr; 54(7):922-8.
Score: 0.005
-
Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009 Sep 15; 49(6):924-7.
Score: 0.005
-
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009 Apr; 142(3):209-217.
Score: 0.004
-
Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol. 2008 Oct; 43(2):190-5.
Score: 0.004
-
Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis. 1987 Aug; 156(2):261-7.
Score: 0.004
-
Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007 Jan 15; 44(2):245-9.
Score: 0.004
-
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl. 2005 Aug; 11(8):941-9.
Score: 0.003
-
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 02; 352(22):2271-84.
Score: 0.003
-
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11.
Score: 0.003
-
Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy. 1983 Sep-Oct; 3(5):275-83.
Score: 0.003
-
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003 Jun; 8(3):183-90.
Score: 0.003
-
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med. 2000 Sep 19; 133(6):435-8.
Score: 0.002
-
A mixed model for factors predictive of pain in AIDS patients with herpes zoster. J Pain Symptom Manage. 1999 Jun; 17(6):410-7.
Score: 0.002
-
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996 Sep 01; 125(5):376-83.
Score: 0.002
-
Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis. 1992 Mar; 165(3):450-5.
Score: 0.001
-
T cell recognition of HIV synthetic peptides in a natural infection. J Immunol. 1989 Feb 15; 142(4):1166-76.
Score: 0.001
-
Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial. Am J Med. 1988 Sep; 85(3):301-6.
Score: 0.001
-
A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J Infect Dis. 1984 Jul; 150(1):1-6.
Score: 0.001